GLSI
Greenwich LifeSciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.95
+2.05%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -23.6%
- EBIT
- -24.0%
- EPS
- -13.2%
- Free cash flow
- -46.9%
- Operating cash flow
- -46.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +17.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- -11.2%
- EBIT
- -10.3%
- Net income
- -11.2%
- EPS
- -18.2%
- Free cash flow
- -36.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026